Navigation Links
New Data Supports Significant Economic and Clinical Value of MENOPUR(R) in IVF
Date:6/30/2009

on in patients undergoing infertility management, it is believed that it will have a major implication on the decision-making process when choosing the appropriate gonadotropin for ovarian stimulation.[1]

"I think the cost-effectiveness of treatments is a real issue for couples considering infertility treatment such as IVF today", says Clare Lewis-Jones from Infertility Network UK. "Despite the economic downturn, we see that couples will somehow find the money for treatment, although many have to make sacrifices in order to do this - it's a question of priorities and the opportunity of having a family is an extremely high priority for infertile couples."

MENOPUR

MENOPUR belongs to a class of drugs known as gonadotropins and contains both FSH (follicle stimulating hormone) and hCG-driven (human chorionic gonadotropin) LH-activity (luteinizing hormone). HP-hMG is used to stimulate the development of multiple follicles in women participating in an ART programme. HP-hMG is also used to treat infertility in women caused by anovulation (low-level production of eggs). MENOPUR is used by over 75,000 patients each year and is currently licensed in over 50 countries across the world

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology and endocrinology. Ferring's fertility portfolio of treatments gives infertile couples the chance to have babies and includes its flagship brand MENOPUR (HP-hMG), a recognised high quality treatment for infertility. Ferring has operating subsidiaries in over 45 countries. To learn more about Ferring or our products please visit http://www.ferring.com.

References:

1. Wex
'/>"/>

SOURCE Ferring Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
2. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
4. Cost-Effectiveness Study Supports Use of EUFLEXXA(TM) by Rheumatologists for Pain Relief in Patients with Knee Osteoarthritis
5. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
6. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
7. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
8. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
11. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... SAN DIEGO , July 29, 2015 /PRNewswire/ ... Thursday, July 23, called the Alvarado Spine & ... orthopedic surgery and rehabilitation, focusing on spinal surgery ... method of patient care takes a patient experience-focused ... whatever clothing they feel comfortable in, rather than ...
(Date:7/29/2015)... FOREST, Calif. , July 29, 2015 ... ("Cryoport" or the "Company"), the leading provider ... life sciences industry, serving markets including immunotherapies, ... vaccine manufacturers, animal health, and reproductive medicine, ... the sale of common stock and warrants (the ...
(Date:7/29/2015)... 29, 2015  Ortho-Clinical Diagnostics, Inc. (OCD) today announced ... The assays address a range of important tests for ... troponin I. The scientific posters will be delivered during ... to be held July 26 - 30 in ... Clinical Diagnostics is emerging stronger than ever since becoming ...
Breaking Medicine Technology:The Alvarado Spine & Joint Institute Opens July 30 in San Diego 2Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 2Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 3
... Texas--(BUSINESS WIRE)--Apr 3, 2007 - Repros,Therapeutics Inc. (NasdaqGM:RPRX) ... of Proellex(TM), an oral drug being developed to,relieve ... with Proellex results in a statistically highly,significant improvement ... well tolerated., Study Details and Results , This ...
... Arrowhead Research,Corporation (NASDAQ: ARWR) announced the publication ... a study,demonstrating the anti-proliferative effect of the ... its lead anti-cancer,compound, CALAA-01., The paper, entitled ... Reduce Cell Proliferation In vitro and In,vivo", ...
Cached Medicine Technology:Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 2Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 3Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 5Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate 2Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate 3
(Date:7/29/2015)... ... ... According to the The Media Post on July 9th teenagers ... medicinal use are more likely to abuse the substance. A recent study conducted by ... beneficial are more apt to use the substance, as opposed to their peers who ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may start ... to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with 78 ...
(Date:7/29/2015)... ... July 29, 2015 , ... The NCCA re-accredited the Commission ... November 30, 2019, during its recent meeting. , The Commission received renewal of ... compliance with the NCCA’s Standards for the Accreditation of Certification Programs. NCCA ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... changed its name in July to Kalamazoo Strength & Conditioning. , The name ... and “reflects the evolution of our training center over the past three years,” ...
(Date:7/29/2015)... ... , ... Today marks a significant achievement in bringing new monies into early ... led by a group of experienced investors, has tapped into an investor community passionate ... be a part of the fund. The Sofia Fund II is now closed ...
Breaking Medicine News(10 mins):Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 2Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4Health News:Sofia Fund Surpasses Investor Goals 2
... published the first comprehensive review of evidence on pneumococcal ... available in the on-line edition of the journal Lancet ... risk of pneumococcal infection by up to 40 fold, ... the PCV, and that the vaccine can protect HIV-infected ...
... San Diego have developed a novel computer technique to ... study, reported November 30 in PLoS Computational Biology relates ... Receptor Modulators (SERMs), which includes tamoxifen, the most prescribed ... side effects account for one-third of all drug development ...
... President of International Operations, MONROVIA, Calif., Nov. ... a leading developer, manufacturer and marketer of,minimally invasive ... has been named President and Chief Executive Officer. ... the annual shareholder,s,meeting in May 2007, replaces David ...
... Nov. 28 Novant Health(R) today announced ... leader,in developing and manufacturing medical devices for ... implement the Cardiocom System in its,Presbyterian Heart ... Hospital is one of the largest healthcare ...
... ASHBURN, Va., Nov. 28 Innocoll, Inc. announced ... that pursuant to,Rule 51(4) EPC, the European Patent ... applications which are both based on its proprietary,CollaRx ... Treatment of,Wounds" and Patent No. 1265648 entitled "Novel ...
... Corporation,("Sosei"; TSE Mothers Index: 4565), a biopharmaceutical company, ... UK Medicines and,Healthcare products Regulatory Agency (MHRA) for ... sublingual spray (AD 923), an opioid,analgesic for the ... trial authorisation (CTA) covers two multi-centre pivotal,Phase III ...
Cached Medicine News:Health News:Pneumococcal conjugate vaccines can improve the lives of HIV-infected children 2Health News:Barry G. Caldwell Named Chief Executive Officer of STAAR Surgical 2Health News:Barry G. Caldwell Named Chief Executive Officer of STAAR Surgical 3Health News:Barry G. Caldwell Named Chief Executive Officer of STAAR Surgical 4Health News:Barry G. Caldwell Named Chief Executive Officer of STAAR Surgical 5Health News:Barry G. Caldwell Named Chief Executive Officer of STAAR Surgical 6Health News:Novant Health(R) Selects Cardiocom(R) to Provide Telemonitoring for Presbyterian Hospital Heart Failure Program 2Health News:Innocoll Receives 'Intends to Grant' Notices from the European Patent Office for Two European Patent Applications Related to Novel Wound Healing, Biosurgery and Drug Delivery Applications of its CollaRx(R) Technology 2Health News:Innocoll Receives 'Intends to Grant' Notices from the European Patent Office for Two European Patent Applications Related to Novel Wound Healing, Biosurgery and Drug Delivery Applications of its CollaRx(R) Technology 3Health News:Innocoll Receives 'Intends to Grant' Notices from the European Patent Office for Two European Patent Applications Related to Novel Wound Healing, Biosurgery and Drug Delivery Applications of its CollaRx(R) Technology 4Health News:Sosei Announces Approval to Start AD 923 Phase III Studies in Europe 2
... Health Record (EHR/EMR) and ... Specialties that we currently ... Cardiology, Dermatology, Family Medicine, ... Neurosurgery, Obstetrics and Gynecology, ...
... Software developed a touchscreen EHR and is ... a user can choose to use a ... maintain eye contact while recording encounter results. ... EHR also runs on a pen tablet ...
Dairylands Health Information Management solutions provides healthcare organizations a suite of integrated applications for managing patient records, optimizing reimbursement and regulatory complianc...
... WEBeDoctor® Physician-office® is ... for physicians, (Solo practice, ... care), to complete their ... practice. It is a ...
Medicine Products: